Astera Labs: revenue doubled, but shares trade at 180 times earnings — growth is already priced in

4 августа Astera Labs раскрыла результаты за второй квартал 2026 года: выручка выросла на 104,5% до 392,4 млн долларов, чистая прибыль — на 199% до 153,1 млн долларов. Компания повышает прогноз на третий квартал до 540–560 млн долларов выручки, но даже с учётом этого акции торгуются по мультипликатору P/E LTM около 180, что делает их скорее непривлекательными на текущей цене.

Key takeaways

— Revenue in Q2 2026 doubled to $392.4 million, and Scorpio switches will become the largest product family in Q3

— Net profit surged 199% to $153.1 million, but nearly half came from a tax benefit

— EBITDA margin expanded to 23.7% from 21.5% a year ago, but operating expenses are growing faster than revenue

— Operating cash flow for the last twelve months was $319.3 million, but the company spends more on R&D than it earns

— Shares rose 12.7% after the report but then fell 6.4% — the market doubts the sustainability of growth

— On the portal's model, the upside potential is only 3% — the valuation is already fair

Attractiveness

Key figures, USD bn

Revenue in Q2 2026 doubled to $392.4 million, and Scorpio switches will become the largest product family in Q3

In Q2 2026, Astera Labs' revenue reached $392.4 million, up 104.5% year-over-year. Growth accelerated from the previous quarter, when revenue rose 93.5% YoY. The company attributes the momentum to a broader product portfolio for AI infrastructure, including record sales of the Aries line.

For Q3, the company guides revenue in the range of $540–560 million, implying over 100% YoY growth. CEO Jitendra Mohan said Scorpio switches will become the largest product family in Q3 — a quarter earlier than previously expected. This marks the company's evolution into a complete AI fabric infrastructure provider.

Net profit surged 199% to $153.1 million, but nearly half came from a tax benefit

Net profit in Q2 2026 was $153.1 million versus $51.2 million a year earlier. However, the report shows a one-off factor: a tax benefit of $50.3 million — the company recorded a tax income instead of an expense. Without this effect, net profit would have been around $103 million.

Net margin rose to 39.0% from 26.7% a year ago, but this is distorted by the tax benefit. GAAP operating income was $89.2 million, implying an operating margin of 22.7%. Investors should focus on operating metrics rather than net profit, which is inflated by the one-off tax effect.

EBITDA margin expanded to 23.7% from 21.5% a year ago, but operating expenses are growing faster than revenue

EBITDA in Q2 2026 grew 126% YoY, and the EBITDA margin expanded to 23.7% from 21.5% a year earlier. This was driven by operating leverage: revenue is growing faster than fixed costs.

However, operating expenses (R&D, sales, and administrative) in Q2 rose to $198.3 million from $105.8 million a year ago — almost doubling. The company is investing heavily in R&D, which could pressure margins in the future if revenue growth slows. For now, economies of scale outweigh.

Operating cash flow for the last twelve months was $319.3 million, but the company spends more on R&D than it earns

For the last twelve months (LTM), Astera Labs' operating cash flow was $319.3 million against net profit of $289.2 million. Capital expenditures over the same period were modest — about $46 million, typical for a fabless semiconductor company.

However, R&D expenses over the last twelve months significantly exceed operating cash flow: in Q2 2026 alone, R&D was $135.9 million, and for the first half — $261.5 million. This means the company spends more on development than it generates from operations, funding the gap with accumulated cash and share issuance.

Shares rose 12.7% after the report but then fell 6.4% — the market doubts the sustainability of growth

On the day of the earnings release, Astera Labs shares rose 12.7%, reflecting strong results and an upgraded outlook. However, from the release to September 9, the stock fell 6.4%, partially giving back the initial optimism.

This dynamic suggests investors are pricing in not only current growth but also risks of deceleration. With a market capitalization of about $52.1 billion and a P/E LTM of around 180, the shares are valued for years of hypergrowth. Any slowdown could lead to a significant correction.

On the portal's model, the upside potential is only 3% — the valuation is already fair

Our fundamental value-creation model, based on EBITDA growth and a target multiple, shows that Astera Labs shares have an upside potential of only +3% to fair value. This means the current price almost fully reflects expected financial performance.

With a P/E LTM of around 180 and ROE of 38%, the shares trade at a significant premium to most companies in the sector, but Astera Labs has no comparable history — it went public only in 2024. Therefore, comparing the multiple to its own three-year history is impossible. Investors who believe in continued growth will have to pay a premium, while those who doubt it will look elsewhere.

Valuation on the latest reported figures

Bottom line

Astera Labs delivered an impressive quarter: revenue doubled, guidance was raised, and Scorpio switches promise to be a new growth driver. However, nearly half of net profit came from a one-off tax benefit, and operating cash flow does not cover rising R&D expenses. With a P/E of around 180 and an upside potential of only 3% on the portal's model, the shares look fairly valued and thus rather unattractive for new investments. The question for holders is whether the company can sustain its growth pace and convert it into cash flow.